What Genomedia does

Genomedia Inc. (Genomedia株式会社) is a Tokyo-based genomic information services company founded in 2013 that delivers genome analysis and clinical data integration solutions specialized for oncology applications in the Japanese healthcare market. Its core products include (i) Genomedia Front / Genomedia Front Cloud Service, a data management system that integrates clinical information with genomic/mutation data and public database content at patient and clinical-trial levels; (ii) QA Commons Lite, a clinical trial search service that uses a proprietary knowledge database to match cancer patients to drug intervention trials in Japan and the US, deployed at over 140 medical institutions as of September 2023; (iii) genome analysis services covering WGS, WES, and RNASeq workflows run from sample preparation through report creation at the company's sanitary testing facility; and (iv) Virtual Sequencing, a deep learning system that predicts cancer genetic abnormalities such as BRAF V600E and MSI-H from H&E-stained pathology images, co-developed with Yokohama City University and National Cancer Center Hospital East and published in Clinical Cancer Research in 2022. Genomedia holds ISO/IEC 27001:2013 and JIS Q 15001:2017 certifications for information security and privacy management.

Name

Genomedia

Legal name

Genomedia株式会社

Website

https://genomedia.jp

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Genomedia is a Tokyo-based genomic information company founded in 2013 that provides WGS/WES/RNASeq analysis, clinical-genomic data integration software (Genomedia Front), a cancer clinical trial matching service (QA Commons Lite), and an AI pathology system (Virtual Sequencing), primarily to Japanese cancer genome medical core hospitals and national screening programs.

Ownership category

akta.pro rank

Product category

Clinical Genomics Software & Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), Services-Computer Programming, Data Processing, Etc. (7370), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)

akta.pro secondary industries

Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), FHIR/HL7 Data Repositories & Canonical Data Models (HLACAIAI), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

Keywords

• Cancer genome analysis
• Clinical genomic data
• Precision medicine software
• Pathology AI screening
• Clinical trial matching

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Genome Analysis Services: WGS/WES/RNASeq analysis services for human specimens (tumor, non-tumor, blood specimens, etc.) from sample preparation through report creation, conducted through a sanitary testing facility.
2. Genomedia® Front (Software/Data Management): Data management software providing clinical and genome information integration, offered as a service with customization capabilities for medical institutions.
3. QA Commons Lite Subscription: Clinical trial search service provided to medical institutions, serving over 140 facilities as of September 2023.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Core offering

Genomedia provides end-to-end cancer genome analysis services (WGS/WES/RNASeq) at its sanitary testing facility, covering everything from sample preparation to clinical report creation. It complements these services with Genomedia Front, a clinical and genomic data integration management platform (available as a cloud service), QA Commons Lite for cancer clinical trial search, and Virtual Sequencing, an AI-based deep learning system that predicts genetic abnormalities from H&E-stained pathological tissue images. Customers are primarily Japanese cancer genome medical core hospitals, affiliated medical institutions, and national cancer research programs.

Product overview

Genomedia is a biotechnology company offering a portfolio of genome analysis and clinical data management products. The core offerings include: Genomedia Front (data management service for integrating clinical and genome/mutation information with cloud service option), QA Commons Lite (clinical trial search service), genome analysis services (WGS/WES/RNASeq), and Virtual Sequencing (AI-powered screening system for predicting genetic abnormalities from pathological images). The products work together to support cancer genome medicine, from sample analysis through data integration and clinical decision support.

Differentiator

Problem solved

Functional benefit

Brands

• Genomedia® Front: Clinical and genomic data integration management system for secure patient-level and clinical trial-level information management and aggregation.
• QA Commons Lite
• Virtual Sequencing

Products and services

• Genomedia Front / Genomedia Front Cloud Service Data management service that integrates clinical information with clinical sequencing/genome and mutation data plus public database information, enabling secure patient-level and clinical trial-level information management and aggregation. Available on-premises and as a cloud service, with customizable fields and proprietary analysis plugin support, sold to medical institutions including cancer genome medical core hospitals and national cancer screening programs.
• QA Commons Lite Subscription-based clinical trial search service for medical institutions that comprehensively organizes and searches Japanese and US cancer clinical trial registry data on drug interventions. Powered by a proprietary knowledge database and matching algorithm; used by over 140 facilities (including cancer genome medical core hospitals and affiliated hospitals) as of September 2023.
• Genome Analysis Service (ゲノム解析サービス) Large-scale genome analysis services conducted at a sanitary testing facility for human specimens (tumor, non-tumor, blood samples), including WGS, WES, and RNASeq analysis. Delivered as one-stop execution from sample preparation through software/tool development to clinical report creation, with ongoing R&D on high-speed, high-efficiency realization methods.
• Virtual Sequencing Deep learning-based screening system that predicts cancer genetic abnormalities (including BRAF V600E and MSI-H) from H&E-stained pathological tissue images, without requiring sequencing. Uses a two-stage detection architecture: first predicting 33 pathological morphological features, then building high-performance genetic abnormality prediction models.
• Genomedia Front Knowledgebase Curated knowledge database that underpins Genomedia Front's drug-mutation-clinical trial matching reports. Comprehensively accumulates and updates cancer-related clinical trial information and drug-gene mutation relationship data to support expert panel interpretation of comprehensive genetic testing results.

Quantifiable outcome

• Virtual Sequencing achieves AUC >0.90 for 12 pathological features and >0.80 for 27 features in detecting BRAF V600E and MSI-H genetic abnormalities
• +3 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• 横浜市立大学 (Yokohama City University)coreStrategic or Co-development Partner · 30 May 2022Joint research collaboration with Yokohama City University Graduate School of Medicine Molecular Pathology department (led by Prof. Satoshi Fujii) and National Cancer Center East Hospital (led by Dr. Takayuki Yoshino) to develop Virtual Sequencing system for predicting cancer genetic abnormalities from pathological tissue images. Results published in Clinical Cancer Research.
• 国立研究開発法人 国立がん研究センター (National Cancer Center Japan)coreStrategic or Co-development Partner · 12 September 2019Genomedia provides Genomedia Front Cloud Service to support SCRUM-Japan, the world's largest cancer genome screening infrastructure. The partnership covers LC-SCRUM-Asia and MONSTAR-SCREEN programs, enabling clinical information and clinical sequencing data integration management for nationwide cancer genome screening initiatives.
• 国立がん研究センター東病院 (National Cancer Center Hospital East)coreStrategic or Co-development PartnerResearch collaboration partner in Virtual Sequencing development, specifically the gastroenterology department led by Dr. Takayuki Yoshino.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Personalis: Cancer genomics company offering NGS-based tumor profiling (ImmunoID Next) and related analytical services to biopharma and providers. Comparable to Genomedia's WGS/WES/RNASeq analysis services and biomarker interpretation capabilities.
• Syapse: Oncology real-world evidence and clinical-genomic data platform serving health systems and life sciences. Comparable to Genomedia Front's integrated clinical-genomic data management for cancer care and research.
• Guardant Health: Liquid biopsy and genomics company providing blood-based tumor profiling (Guardant360) and biopharma data services. Overlaps with Genomedia's cancer genomic profiling and clinical-genomic data infrastructure for screening programs.
• Tempus Labs: AI-driven precision medicine company offering molecular profiling, clinical-genomic data integration, and clinical trial matching for oncology. Directly comparable to Genomedia across analysis services, data management SaaS, and clinical decision support, though at far greater scale and geographic reach.
• Caris Life Sciences: Molecular profiling and AI-driven precision medicine company offering whole-exome/transcriptome sequencing (MI Profile) and a biopharma data platform. Comparable to Genomedia across WES/RNAseq services and clinical-genomic data integration.
• Veracyte: Genomic diagnostics company focused on oncology and pulmonology, providing molecular testing and a data platform. Comparable in clinical-genomic decision support and hospital-channel distribution, though primarily tissue-based rather than blood-based profiling.

Broad incumbents

• Foundation Medicine (Roche): Pioneer in comprehensive genomic profiling (FoundationOne CDx) for solid tumors with broad pharma and provider relationships. Competes with Genomedia's sequencing services and clinical interpretation workflows for Japanese hospital accounts.

Emerging players

• Molecular Health: Precision medicine informatics company offering genomic-clinical decision support software and curated knowledge databases for variant and drug interpretation. Closely aligned with Genomedia Front Knowledgebase and QA Commons Lite clinical-trial matching.

Regional players

• DNA Chip Research: Japanese genomics services company providing microarray- and sequencing-based analysis to pharma and academic customers. Most directly comparable Japanese peer for Genomedia's analysis services and clinical-genomic data offerings.
• Sysmex: Japanese diagnostics leader offering in-vitro diagnostics, hematology, and increasingly oncology molecular testing. A natural Japan-based competitor and potential acquirer/partner for Genomedia's hospital sequencing services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/genomediainc

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genomedia